A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Of Deferasirox In Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) And Transfusional Iron Overload (Telesto).
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2018
At a glance
- Drugs Deferasirox (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Acronyms TELESTO
- Sponsors Novartis Pharmaceuticals
- 17 Jul 2018 Status changed from active, no longer recruiting to completed.
- 25 May 2018 This trial has been completed in Greece (end date: 2018-02-27)
- 10 Jun 2017 Biomarkers information updated